Signal transduction in mammary tumorigenesis: a transgenic perspective

[1]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[2]  Tony Pawson,et al.  Mammalian Grb2 Regulates Multiple Steps in Embryonic Development and Malignant Transformation , 1998, Cell.

[3]  G. Ruvkun,et al.  The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. , 1998, Molecular cell.

[4]  Marius Sudol,et al.  From Src Homology domains to other signaling modules: proposal of the `protein recognition code' , 1998, Oncogene.

[5]  Channing J Der,et al.  Increasing complexity of Ras signaling , 1998, Oncogene.

[6]  John N. Hutchinson,et al.  Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis , 1998, Molecular and Cellular Biology.

[7]  S. Bull,et al.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Yarden,et al.  The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. , 1998, Biochimica et biophysica acta.

[9]  T. Pawson,et al.  Signaling through scaffold, anchoring, and adaptor proteins. , 1997, Science.

[10]  M. Moran,et al.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.

[11]  Asim Khwaja,et al.  Matrix adhesion and Ras transformation both activate a phosphoinositide 3‐OH kinase and protein kinase B/Akt cellular survival pathway , 1997, The EMBO journal.

[12]  M. Shibuya,et al.  Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation , 1997, Molecular and cellular biology.

[13]  N. Hay,et al.  The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. , 1997, Genes & development.

[14]  A. Klippel,et al.  Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.

[15]  G. Evan,et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.

[16]  F. McCormick,et al.  Signal transduction from multiple Ras effectors. , 1997, Current opinion in genetics & development.

[17]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[18]  R. Cardiff,et al.  Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice , 1996, Molecular and cellular biology.

[19]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[20]  M. Loda,et al.  CDC25 phosphatases as potential human oncogenes. , 1995, Science.

[21]  B. Abeles,et al.  Transport in solid oxide porous electrodes: Effect of gas diffusion , 1995 .

[22]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[23]  R. Cardiff,et al.  Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Maa,et al.  Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Ravdin,et al.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.

[26]  T. Pawson,et al.  A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides , 1995, Current Biology.

[27]  L. Cantley,et al.  Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3(*) , 1995, The Journal of Biological Chemistry.

[28]  G. Cooper,et al.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.

[29]  G. Boss,et al.  Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[31]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[32]  T. Roberts,et al.  Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Y. Yarden,et al.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.

[34]  L. Cantley,et al.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.

[35]  W. Gullick,et al.  Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.

[36]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[37]  T Pawson,et al.  Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav , 1994, Molecular and cellular biology.

[38]  P. D’Eustachio,et al.  The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.

[39]  W. Dougall,et al.  Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Michael D. Jones,et al.  Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc , 1994, Nature.

[41]  M. Luther,et al.  Involvement of pp60c-src with two major signaling pathways in human breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Ravdin,et al.  Prognostic factors in early breast carcinoma , 1994, Cancer.

[43]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[44]  B. Groner,et al.  An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice , 1993, The Journal of cell biology.

[45]  M. Wigler,et al.  Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. , 1993, Science.

[46]  Julian Downward,et al.  Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor , 1993, Cell.

[47]  Nanxin Li,et al.  Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling , 1993, Nature.

[48]  D. Bar-Sagi,et al.  Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras , 1993, Nature.

[49]  R. Weinberg,et al.  Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation , 1993, Nature.

[50]  T. Pawson,et al.  The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1 , 1993, Nature.

[51]  E. Schuuring,et al.  The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites , 1993, Molecular and cellular biology.

[52]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[53]  R. Peterson.  A nursing intervention for early detection of spinal cord compressions in patients with cancer , 1993, Cancer nursing.

[54]  Sheila M. Thomas,et al.  Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases , 1992, Nature.

[55]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Boracchi,et al.  Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. , 1992, British Journal of Cancer.

[57]  T. Pawson,et al.  Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Roberts,et al.  Polyomavirus middle T-antigen NPTY mutants , 1992, Journal of virology.

[59]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[60]  V. Brown,et al.  Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  A. Villa,et al.  Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. , 1992, Cancer letters.

[62]  R. Lupu,et al.  Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[63]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[64]  K. Dobashi,et al.  Characterization of a neu/c-erbB-2 protein-specific activating factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[65]  C. Molloy,et al.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency , 1991, Molecular and cellular biology.

[66]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[67]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[68]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[69]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[70]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[71]  S. Feig,et al.  Heterogeneity of intraductai carcinoma of the breast , 1989 .

[72]  T. Roberts,et al.  Mechanisms of transformation by polyoma virus middle T antigen. , 1989, Biochimica et biophysica acta.

[73]  C. Benz,et al.  Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. , 1989, Cancer research.

[74]  K. Semba,et al.  Peptide antibodies to the human c‐fyn gene product demonstrate pp59c‐fyn is capable of complex formation with the middle‐T antigen of polyomavirus. , 1988, The EMBO journal.

[75]  S. Courtneidge,et al.  Identification and characterization of p59fyn (a src‐like protein tyrosine kinase) in normal and polyoma virus transformed cells. , 1988, The EMBO journal.

[76]  B. Angus,et al.  Epidermal growth factor receptor status of histological sub-types of breast cancer. , 1988, British Journal of Cancer.

[77]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[78]  L. Luttrell,et al.  Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src , 1988, Molecular and cellular biology.

[79]  A. Smith,et al.  Mutants of polyomavirus middle-T antigen. , 1987, Biochimica et biophysica acta.

[80]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[81]  B. Groner,et al.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[82]  H. Hanafusa,et al.  Association of the polyomavirus middle-T antigen with c-yes protein , 1987, Nature.

[83]  T Pawson,et al.  A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps , 1986, Molecular and cellular biology.

[84]  B. Oostra,et al.  Site-directed mutagenesis of polyomavirus middle-T antigen sequences encoding tyrosine 315 and tyrosine 250 , 1986, Journal of virology.

[85]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[86]  G. Carmichael,et al.  Transformation by polyoma virus is drastically reduced by substitution of phenylalanine for tyrosine at residue 315 of middle-sized tumor antigen. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Alan E. Smith,et al.  Polyoma virus transforming protein associates with the product of the c-src cellular gene , 1983, Nature.

[88]  M. Israel,et al.  Interrupting the early region of polyoma virus DNA enhances tumorigenicity. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A-M Cleton-Jansen,et al.  Expression profiling of BRCA1 associated breast tumors , 2000, Breast Cancer Research.

[90]  M. Greene,et al.  Genetics of breast cancer. , 1997, Mayo Clinic proceedings.

[91]  R. Dickson,et al.  Mammary Tumor Cell Cycle, Differentiation, and Metastasis , 1996, Cancer Treatment and Research.

[92]  W. Dougall,et al.  Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase-inactive p185c-neu. , 1996, DNA and cell biology.

[93]  R. Cardiff,et al.  Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.

[94]  R. Cardiff,et al.  Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.

[95]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.